- Home
- NRXP vs MAIA Comparison
NRXP vs MAIA Comparison
Compare NRXP & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXP
- MAIA
- Stock Information
- Founded
- NRXP 2015
- MAIA 2018
- Country
- NRXP United States
- MAIA United States
- Employees
- NRXP N/A
- MAIA N/A
- Industry
- NRXP Biotechnology: Pharmaceutical Preparations
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- NRXP Health Care
- MAIA Health Care
- Exchange
- NRXP Nasdaq
- MAIA Nasdaq
- Market Cap
- NRXP 58.5M
- MAIA 56.3M
- IPO Year
- NRXP N/A
- MAIA 2022
- Fundamental
- Price
- NRXP $2.89
- MAIA $1.58
- Analyst Decision
- NRXP Strong Buy
- MAIA
- Analyst Count
- NRXP 4
- MAIA 0
- Target Price
- NRXP $28.50
- MAIA N/A
- AVG Volume (30 Days)
- NRXP 283.3K
- MAIA 398.8K
- Earning Date
- NRXP 08-19-2025
- MAIA 08-11-2025
- Dividend Yield
- NRXP N/A
- MAIA N/A
- EPS Growth
- NRXP N/A
- MAIA N/A
- EPS
- NRXP N/A
- MAIA N/A
- Revenue
- NRXP N/A
- MAIA N/A
- Revenue This Year
- NRXP N/A
- MAIA N/A
- Revenue Next Year
- NRXP $230.95
- MAIA N/A
- P/E Ratio
- NRXP N/A
- MAIA N/A
- Revenue Growth
- NRXP N/A
- MAIA N/A
- 52 Week Low
- NRXP $1.10
- MAIA $1.40
- 52 Week High
- NRXP $6.01
- MAIA $3.74
- Technical
- Relative Strength Index (RSI)
- NRXP 54.48
- MAIA 45.57
- Support Level
- NRXP $2.30
- MAIA $1.50
- Resistance Level
- NRXP $2.68
- MAIA $1.73
- Average True Range (ATR)
- NRXP 0.19
- MAIA 0.09
- MACD
- NRXP 0.02
- MAIA 0.01
- Stochastic Oscillator
- NRXP 89.39
- MAIA 42.86
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.